Open now · Cooperative Agreement · PAR-28-042
The purpose of the Notice of Funding Opportunity (NOFO) is to support the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. Utilizing either a phased UH2/UH3 or a standalone UH3 mechanism, funding will facilitate laboratory optimization and clinical validation of assays that work on human samples and address a clearly defined cancer-related clinical need within a well-specified intended use.
| Item | Estimate | Note |
|---|---|---|
| Drafting effort | 3–4 weeks | single submission |
| Time to first payment | 6–9 months | cut-off → evaluation → grant agreement |
These are Bemzu's estimates from the call's structure (the number of stages and whether a consortium is required) not figures published by the Commission. Only the co-financing share is read from the call itself.
Eight questions, no account, nothing sent anywhere. You will know which of the 1469 open calls you can actually enter before you finish your coffee.
Check my fit
